IGF1 and cancer: It has been hypothesized that NSCLC cancers may have both metabolic and mitogenic advantages from the increased IR-A:IR-B ratio, and therefore an evaluation of the IR isoforms before starting a treatment targeting the IGF pathway could be helpful [43].